US FDA approves Jazz Pharmaceuticals’ Modeyso to treat recurrent H3 K27M-mutant diffuse midline glioma: Dublin Friday, August 8, 2025, 11:00 Hrs [IST] Jazz Pharmaceuticals plc, ...

Analysis leads to FDA RMAT submission and late-breaking abstract for implantable cell therapy - NEWARK, Del., Aug. 7, 2025 ...

Modeyso is the first and only approved treatment for recurrent H3 K27M-mutant diffuse midline glioma in patients aged one ...

Modeyso is the first drug to treat patients with diffuse midline glioma with an H3 K27M mutation, an ultra-rare and aggressive brain tumor.

The FDA granted accelerated approval to dordaviprone for the treatment of patients aged 1 year and older with recurrent diffuse midline glioma who harbor the H3 K27M mutation with progressive disease ...

The Nigeria Police Force said it has observed with concern the growing wave of lobbying and unofficial requests to ...

Company on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) under accelerated approval pathway in ...

The Nigeria Police Force has raised concerns over a rising trend of lobbying and unofficial promotion requests directed at ...

The US FDA has given accelerated approval to Jazz Pharma for Modeyso to treat adult and paediatric patients with diffuse midline glioma.

The FDA has granted accelerated approval to Modeyso (dordaviprone) for the treatment of certain patients with diffuse midline glioma.

Jazz Pharmaceuticals bet $1 billion on the commercial potential of a first-in-class oral imipridone for recurrent H3 K27M-mutant diffuse glioma.

The FDA granted accelerated approval to dordaviprone (Modeyso) as the first systemic therapy for adults and children with ...